Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$19.69−1.72 (-8.03%)
Close on Nov 17, 2026Market cap $1.87BP/E –Yield –
Replimune free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Replimune's free cash flow for the twelve months ending Sep 30, 2026 was -$245.77M. For fiscal 2026 it was -$284.57M. The highest annual figure on record is -$7.32M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$284.57M | – |
| FY2025 | Mar 31, 2025 | -$198.94M | – |
| FY2024 | Mar 31, 2024 | -$191.13M | – |
| FY2023 | Mar 31, 2023 | -$130.32M | – |
| FY2022 | Mar 31, 2022 | -$84.52M | – |
| FY2021 | Mar 31, 2021 | -$63.78M | – |
| FY2020 | Mar 31, 2020 | -$67.09M | – |
| FY2019 | Mar 31, 2019 | -$27.98M | – |
| FY2018 | Mar 31, 2018 | -$16.15M | – |
| FY2017 | Mar 31, 2017 | -$7.32M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | -$47.78M | – |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$75.73M | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$56.17M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$66.09M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$82.56M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$79.76M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$54.87M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$52.51M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$40.72M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$50.84M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$47.91M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$48.84M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$45.34M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$49.04M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$33.05M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$29.14M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$33.61M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$34.52M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$23.71M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$18.81M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$23.39M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$18.61M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$16.90M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$13.61M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$17.25M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$16.02M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$12.60M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$19.79M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$20.76M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$13.94M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$7.88M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$6.74M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$6.39M | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$6.98M | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$4.23M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$2.70M | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$3.69M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$5.53M | – |
See a number that looks wrong?